The DOI matches its Crossref record.
WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients – results from a single‐centre study
Open accessAbstract
Summary: Following induction chemotherapy for acute myeloid leukaemia (AML), sensitive determination of minimal residual disease (MRD) in patients achieving complete remission (CR) should enable the detection of early relapse and allow intervention at a more favourable stage than at overt relapse. We have determined the expression levels of the Wilms’ tumour gene (WT1) by real‐time quantitative polymerase chain reaction (RQ‐PCR) in peripheral blood and bone marrow in 133 newly diagnosed AML patients and compared them with those in healthy volunteers. At diagnosis, the WT1 level exceeded normal expression in 118 of 133 (89%) patients, and was high enough to allow for detection of a WT1 decrease of least 1000‐fold in 98 of 133 (74%) patients following induction therapy. Concomitant monitoring of fusion transcripts (PML‐RARα, AML1‐ETO, MLL‐MLL, CBFβ‐MYH11, or DEK‐CAN) in 38 patients identified different relationships between WT1 and fusion transcript levels, the AML1‐ETO group showing remarkably low levels of WT1 compared with fusion transcript. In 32 patients analysed longitudinally there was close concordance between relapse and increased WT1 levels. Parallel longitudinal monitoring of WT1 and fusion transcript showed close correlation in 18 of 18 patients. We conclude that WT1 expression by RQ‐PCR may be employed as a tool to detect MRD in the majority of fusion transcript‐negative AML patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Telomerase and cancer therapeutics
Harley, C. B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2275 · Cited by 728
A tumor suppressor and oncogene: the WT1 story
Yang, L., Han, Y., Saurez Saiz, F., & Minden, M. D. (2007) · Leukemia · doi:10.1038/sj.leu.2404624 · Cited by 471
Cilloni, D., Renneville, A., Hermitte, F., Hills, R. K., Daly, S., Jovanovic, J. V., Gottardi, E., Fava, M., Schnittger, S., Weiss, T., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4865 · Cited by 445
Rezvani, K., Yong, A. S. M., Mielke, S., Savani, B. N., Musse, L., Superata, J., Jafarpour, B., Boss, C., & Barrett, A. J. (2008) · Blood · doi:10.1182/blood-2007-08-108241 · Cited by 341
Khoury, H. J., Collins, R. H., Blum, W., Stiff, P. S., Elias, L., Lebkowski, J. S., Reddy, A., Nishimoto, K. P., Sen, D., Wirth, E. D., et al. (2017) · Cancer · doi:10.1002/cncr.30696 · Cited by 102
Metadata
- Authors
- Østergaard, M., Olesen, L. H., Hasle, H., Kjeldsen, E., & Hokland, P.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2004-04-27
- Volume
- 125
- Issue
- 5
- Pages
- 590-600
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2021380995
- Cited by
- 200
- References
- 0
- FWCI
- 6.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients – results from a single‐centre study. https://app.cochat.ai/papers/10.1111/j.1365-2141.2004.04952.x
- The paper
- Østergaard, M., Olesen, L. H., Hasle, H., Kjeldsen, E., & Hokland, P. (2004). WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients – results from a single‐centre study. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2004.04952.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.